Metagenomi Unveils Compact SMART Gene Editing Platform at CRISPR Conference

Metagenomi's SMART Platform: A Breakthrough in Compact Gene Editing

Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company, has unveiled its innovative SMART (Small Modular Adenine base editors that are Robust and Tunable) gene editing platform at the American Institute of Chemical Engineers (AIChE) 7th International Conference on CRISPR Technologies in San Diego 1

1

2

2

. The presentation, titled "Engineering of compact and efficient adenine base editors from metagenomic derived systems," showcased the company's progress in developing a gene editing tool that could potentially overcome key challenges in in vivo gene therapy.

Compact Design for Efficient Delivery

The SMART platform addresses a critical limitation in current gene editing technologies: the size of editing components. Traditional tools like SpCas9 are too large to fit within a single adeno-associated virus (AAV) vector, which is the preferred method for delivering genetic material to tissues outside the liver 1

1

. Metagenomi's SMART system, however, is compact enough to be packaged into a standard AAV vector, even with additional base editing domains included 2

2

.

This breakthrough could have significant implications for treating neuromuscular diseases such as Duchenne muscular dystrophy (DMD), familial amyotrophic lateral sclerosis (ALS), and Charcot-Marie-Tooth disease type 1A (CMT1A). By enabling efficient delivery to extrahepatic tissues, the SMART platform may offer a more effective and streamlined approach to gene therapy for these conditions 1

1

2

2

.

Multi-Faceted Development Approach

Metagenomi has employed a diverse strategy to optimize the SMART platform since its initial discovery:

1. Structure-guided engineering: Collaboration with Professor David Taylor's lab at UT Austin has provided insights into the structural aspects of the SMART system 1

   1

   2

   2

   .

2. Artificial Intelligence: Advanced AI tools, trained on natural SMART enzymes, have been applied to further refine the platform. This AI-driven approach was presented earlier this year at the Cold Spring Harbor Laboratory (CSHL) CRISPR Frontiers conference 1

   1

   2

   2

   .

Potential Impact and Future Directions

Chris Brown, PhD and Head of Discovery at Metagenomi, expressed enthusiasm about the platform's progress, stating, "We demonstrated that our SMART nucleases can be engineered into functional base editors within the packaging limits of standard AAV. We believe the improved editing efficiency of these SMART systems will enable pursuit of neuromuscular targets, either on our own or in partnerships." 1

1

2

2

The SMART platform's ability to package into a single AAV vector could potentially simplify the manufacturing process, reduce required dosages, and increase overall editing efficiency compared to dual AAV systems necessitated by larger editing tools 1

1

2

2

.

Metagenomi's Unique Approach

Metagenomi's approach leverages metagenomics, studying genetic material from natural environments, to develop a comprehensive toolbox for genetic medicine. This strategy has allowed the company to create a diverse array of editing tools, including programmable nucleases, base editors, and RNA and DNA-mediated integration systems 1

1

2

2

.

As the field of genetic medicine continues to evolve, Metagenomi's SMART platform represents a significant step forward in addressing the challenges of in vivo gene editing. The company's innovative approach, combining metagenomics, structural biology, and artificial intelligence, showcases the potential for interdisciplinary collaboration in advancing next-generation gene editing systems.